Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Hold” by Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has earned a consensus rating of “Hold” from the thirteen analysts that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.70.

Several research firms have issued reports on AARD. Morgan Stanley reaffirmed an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. BTIG Research downgraded Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Stifel Nicolaus reaffirmed a “hold” rating and set a $6.00 price target (down from $24.00) on shares of Aardvark Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada cut Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $18.00 to $6.00 in a report on Monday, March 2nd. Finally, B. Riley Financial dropped their price objective on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, May 15th.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD opened at $3.90 on Monday. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.94. The company has a 50-day moving average of $4.69 and a two-hundred day moving average of $8.86. The company has a market cap of $85.10 million, a PE ratio of -1.21 and a beta of 4.50.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. As a group, equities research analysts forecast that Aardvark Therapeutics will post -3.46 earnings per share for the current year.

Institutional Investors Weigh In On Aardvark Therapeutics

Institutional investors have recently modified their holdings of the business. UBS Group AG raised its stake in shares of Aardvark Therapeutics by 5.4% during the third quarter. UBS Group AG now owns 54,728 shares of the company’s stock worth $727,000 after buying an additional 2,804 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Aardvark Therapeutics in the second quarter valued at approximately $42,000. Bank of America Corp DE grew its holdings in Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after acquiring an additional 3,369 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aardvark Therapeutics during the 4th quarter valued at $47,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Aardvark Therapeutics during the 4th quarter valued at $56,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.